These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39322226)

  • 1. Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis Registry.
    Silverberg JI; Gold LS; Desai S; Golant A; DiRuggiero D; Fenske DC; Li A; Dawson Z; Muñoz Maldonado Y; Ho K; Callahan K; Simpson EL
    J Dermatolog Treat; 2024 Dec; 35(1):2396382. PubMed ID: 39322226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry.
    Silverberg JI; Pierce E; Feely M; Atwater AR; Schrader A; Jones EA; Dave SS; Simpson EL
    J Dermatolog Treat; 2023 Dec; 34(1):2246601. PubMed ID: 37691405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
    Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Tajima Y; Ardeleanu M; Rizova E; Arima K;
    J Dermatol; 2019 Apr; 46(4):290-300. PubMed ID: 30756423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study.
    Bruin-Weller M; Pink AE; Patrizi A; Gimenez-Arnau AM; Agner T; Roquet-Gravy PP; Ferrucci SM; Arenberger P; Svensson A; Schuttelaar MLA; Nosbaum A; Jayawardena S; Rizova E; Ardeleanu M; Eckert L; Ozturk ZE
    J Dermatolog Treat; 2021 Mar; 32(2):164-173. PubMed ID: 33461356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
    Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Paller AS; Tan JKL; Bagel J; Rossi AB; Shumel B; Zhang H; Abramova A
    Br J Dermatol; 2022 Mar; 186(3):496-507. PubMed ID: 34726270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
    Simpson EL; Guttman-Yassky E; Margolis DJ; Feldman SR; Qureshi A; Hata T; Mastey V; Wei W; Eckert L; Chao J; Arnold RJG; Yu T; Vekeman F; Suárez-Fariñas M; Gadkari A
    JAMA Dermatol; 2018 Aug; 154(8):903-912. PubMed ID: 29971354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
    Guttman-Yassky E; Bar J; Rothenberg-Lausell C; Eichenfield L; Grada A; Abuabara K; Chapman M; Calimlim B; Wegzyn C; Gamelli A; Krueger W; Munoz B; Knapp K; Faller R; Crawford J; Silverberg J
    J Drugs Dermatol; 2023 Apr; 22(4):344-354. PubMed ID: 37026893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
    Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF;
    J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry.
    Silverberg JI; Shi VY; Alexis A; Pierce E; Cronin A; McLean RR; Roberts-Toler C; Rueda MJ; Atwater AR; Simpson E
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2045-2061. PubMed ID: 37481484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
    Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
    Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study.
    Darbellay B; Huber M; Bisschoff IJ; Guillod C; Hügel R; Pirkhammer D; Sator PG; Taskesen T; Lang CCV
    J Dermatolog Treat; 2024 Dec; 35(1):2415407. PubMed ID: 39419511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
    Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
    J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Br J Dermatol; 2021 May; 184(5):888-895. PubMed ID: 32959390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
    Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
    Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y; Ding RL; Bu J
    Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.